An international multi-centre open-label 2-arm phase III trial of adjuvant R435(bevacizumab) in "triple negative" breast cancer.

Category Primary study
Registry of TrialsJapan Primary Registry Network
Year 2008
This article has no abstract
Epistemonikos ID: 1c661d6ea2b19bcd4d716e5ff4a3eeeee2d54215
First added on: Apr 16, 2025